Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.15 HKD | +6.48% | +4.18% | -15.44% |
Apr. 17 | Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer | CI |
Apr. 02 | Hutchmed endometrial cancer treatment application accepted for review | AN |
Business Summary
Number of employees: 4,872
Sales per Business
HKD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 5,146 | 100.0 % | 5,299 | 100.0 % | +2.97% |
Sales per region
HKD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
China
90.7
%
| 4,782 | 92.9 % | 4,806 | 90.7 % | +0.50% |
United States
9.0
%
| 315 | 6.1 % | 478 | 9.0 % | +51.58% |
Indonesia
0.3
%
| 8 | 0.2 % | 15 | 0.3 % | +87.12% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
De Chao Yu
CEO | Chief Executive Officer | 61 | 11-04-27 |
Fei You
DFI | Director of Finance/CFO | 45 | Feb. 04 |
Yong-Jun Liu
PSD | President | - | 20-10-14 |
Ghang Shou Gao
CTO | Chief Tech/Sci/R&D Officer | - | - |
Qin Wei Zhou
COO | Chief Operating Officer | 61 | 16-06-15 |
Hao Xi Ede
BRD | Director/Board Member | 65 | 17-06-04 |
Vivian Zhang
HRO | Human Resources Officer | - | 12-02-29 |
Blake Salisbury
PRN | Corporate Officer/Principal | - | 16-02-29 |
Yan Ju Wang
SEC | Corporate Secretary | 36 | 15-09-30 |
Lok Yee Chan
SEC | Corporate Secretary | 35 | 18-06-03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Zieziula
BRD | Director/Board Member | 69 | 22-05-30 |
Charles Cooney
BRD | Director/Board Member | 80 | 15-10-17 |
De Chao Yu
CEO | Chief Executive Officer | 61 | 11-04-27 |
I Yin Hsu
BRD | Director/Board Member | 50 | 18-10-17 |
Hao Xi Ede
BRD | Director/Board Member | 65 | 17-06-04 |
Kai Xian Chen
BRD | Director/Board Member | 79 | 18-10-17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,622,682,897 | 1,509,307,058 ( 93.01 %) | 0 | 93.01 % |
Company contact information
Innovent Biologics, Inc.
168 Dongping Street Suzhou Industrial Park
215123, Suzhou
+86 512 6956 6088
http://www.innoventbio.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.09% | 7.03B | |
-2.72% | 85.68B | |
+5.53% | 41.4B | |
-24.99% | 28.22B | |
+54.63% | 24.64B | |
-7.19% | 16.98B | |
-34.20% | 13.29B | |
-17.31% | 11.66B | |
-11.43% | 11.65B | |
-1.57% | 8.18B |
- Stock Market
- Equities
- 1801 Stock
- Company Innovent Biologics, Inc.